Answers are grounded in this paper and cite their sources.
Observational analysis reveals that a pepducin enhances G protein signaling while inhibiting b-arrestin interactions.
Pepducins are synthetic membrane-tethered lipopeptides designed to allosterically modulate G protein-coupled receptor (GPCR) signaling. Here, we characterize a series of pepducins targeting the neurotensin receptor type 1 (NTS1), revealing multifaceted modulation of this receptor class. Using BRET-based biosensors, we show that PP-001, a pepducin derived from NTS1's first intracellular loop, preferentially activates G protein over b-arrestin signaling while inhibiting NT binding, NT-induced b-arrestin recruitment, and NTS1 receptor internalization, thereby acting as biased allosteric agonist and negative allosteric modulator. PP-001 also promotes the formation of both homo- and heteromeric multi-receptor units. In vivo, PP-001 elicits potent, sustained hypotensive effects, reversible by the NTS1 antagonist SR48692. Finally, although the mechanism of pepducin-receptor interaction remains unclear, this study identifies a critical N-terminal RKK motif for PP-001's biological activity. Thermodenaturation assays with purified NTS1 and mutagenesis further provide evidence for the role of NTS1's H8 domain in direct pepducin-receptor interaction. This work highlights pepducins' modulatory potential as pharmacological tools for GPCR-targeted drug development.
No takes yet. Share an insight, caveat, or question.
Brouillette et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: